Bio-Reference Laboratories Misses on Revenues but Beats on EPS

Before you go, we thought you'd like these...
Before you go close icon

Bio-Reference Laboratories (NAS: BRLI) reported earnings on Feb. 28. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Jan. 31 (Q1), Bio-Reference Laboratories missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew. GAAP earnings per share grew significantly.


Gross margins contracted, operating margins grew, net margins grew.

Revenue details
Bio-Reference Laboratories recorded revenue of $161.3 million. The five analysts polled by S&P Capital IQ foresaw sales of $165.3 million on the same basis. GAAP reported sales were 7.6% higher than the prior-year quarter's $149.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.31. The five earnings estimates compiled by S&P Capital IQ anticipated $0.28 per share. GAAP EPS of $0.31 for Q1 were 19% higher than the prior-year quarter's $0.26 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 44.0%, 550 basis points worse than the prior-year quarter. Operating margin was 9.8%, 90 basis points better than the prior-year quarter. Net margin was 5.4%, 50 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $183.4 million. On the bottom line, the average EPS estimate is $0.40.

Next year's average estimate for revenue is $737.8 million. The average EPS estimate is $1.76.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 314 members out of 333 rating the stock outperform, and 19 members rating it underperform. Among 102 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 97 give Bio-Reference Laboratories a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Reference Laboratories is outperform, with an average price target of $31.00.

Is Bio-Reference Laboratories the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

The article Bio-Reference Laboratories Misses on Revenues but Beats on EPS originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Bio-Reference Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners